IL315501A - Methods for treating cancer and other conditions with a mu-opioid receptor antagonist - Google Patents

Methods for treating cancer and other conditions with a mu-opioid receptor antagonist

Info

Publication number
IL315501A
IL315501A IL315501A IL31550124A IL315501A IL 315501 A IL315501 A IL 315501A IL 315501 A IL315501 A IL 315501A IL 31550124 A IL31550124 A IL 31550124A IL 315501 A IL315501 A IL 315501A
Authority
IL
Israel
Prior art keywords
conditions
methods
receptor antagonist
treating cancer
opioid receptor
Prior art date
Application number
IL315501A
Other languages
English (en)
Hebrew (he)
Original Assignee
Glycyx Mor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycyx Mor Inc filed Critical Glycyx Mor Inc
Publication of IL315501A publication Critical patent/IL315501A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL315501A 2022-03-10 2023-03-10 Methods for treating cancer and other conditions with a mu-opioid receptor antagonist IL315501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263318465P 2022-03-10 2022-03-10
PCT/US2023/064088 WO2023173055A2 (en) 2022-03-10 2023-03-10 Methods of treating cancer and other conditions with a mu opioid receptor antagonist

Publications (1)

Publication Number Publication Date
IL315501A true IL315501A (en) 2024-11-01

Family

ID=87936037

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315501A IL315501A (en) 2022-03-10 2023-03-10 Methods for treating cancer and other conditions with a mu-opioid receptor antagonist

Country Status (10)

Country Link
US (1) US20250186423A1 (https=)
EP (1) EP4489866A4 (https=)
JP (1) JP2025508131A (https=)
KR (1) KR20250004644A (https=)
CN (1) CN119584986A (https=)
AU (1) AU2023231655A1 (https=)
CA (1) CA3253916A1 (https=)
IL (1) IL315501A (https=)
TW (1) TW202400158A (https=)
WO (1) WO2023173055A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025137697A1 (en) * 2023-12-21 2025-06-26 Glycyx Mor Inc. Methods, systems, and compositions related to use of mu opioid receptor (mor) antagonists
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
JP6686013B2 (ja) * 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
US12053523B2 (en) * 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
US11471459B2 (en) * 2018-03-26 2022-10-18 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Compounds with enhanced anti-tumor effects
US20220125844A1 (en) * 2020-10-23 2022-04-28 The Johns Hopkins University Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy

Also Published As

Publication number Publication date
JP2025508131A (ja) 2025-03-21
TW202400158A (zh) 2024-01-01
EP4489866A2 (en) 2025-01-15
CN119584986A (zh) 2025-03-07
KR20250004644A (ko) 2025-01-08
WO2023173055A2 (en) 2023-09-14
US20250186423A1 (en) 2025-06-12
AU2023231655A1 (en) 2024-10-17
EP4489866A4 (en) 2026-03-11
CA3253916A1 (en) 2023-09-14
WO2023173055A3 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
IL315501A (en) Methods for treating cancer and other conditions with a mu-opioid receptor antagonist
WO2009117669A3 (en) Treatment with opioid antagonists and mtor inhibitors
GB2594788B (en) Antagonist of PCSK9
IL276462A (en) Methods for the production of morphine alkaloids and derivatives
ZA202201500B (en) Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer
WO2011020030A3 (en) Methods and compositions to prevent addiction
IL279548A (en) Methods for treating lung cancer with a PD-1 spindle-binding antagonist, a platinum agent, and a topoisomerase II inhibitor
ZA202212305B (en) Crystal of m receptor antagonist as well as preparation method therefor and application thereof
HK40120815A (en) Methods of treating cancer and other conditions with a mu opioid receptor antagonist
EP4168033A4 (en) CEBP-BETA ANTAGONIST ADMINISTRATION AND METHODS OF USE
GB2617100B (en) Implantable bioelectronic device and method of using same
IL312187A (en) Methods for treating prurigo nodularis by administering an IL-4R antagonist
EP4168016A4 (en) METHOD OF TREATING CANCER OR VON HIPEL LINDAU DISEASE WITH A COMBINATION OF A PD-1 ANTAGONIST, A HIF-2 ALPHA INHIBITOR AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
HUE070513T2 (hu) Rákos megbetegedések szekvenciális kezelése 6-tio-DG és checkpoint-inhibitorok alkalmazásával
GB202502834D0 (en) Methods and systems for transdermally stimulating a muscle
IL310168A (en) Standards and methods for placing steel bars to reinforce concrete
IL311402A (en) A method for treating cancer by combining btk inhibitors with pi3 kinase inhibitors
IL320431A (en) Crystalline forms of zibagen hydrochloride and process for their preparation
IL318016A (en) Methods for treating eosinophilic esophagitis in children by administering an IL-4R antagonist
IL289068A (en) Preparations and methods for the treatment of cannabinoid hyperemesis syndrome using a cannabinoid receptor antagonist
HK40094667A (en) Crystalline edg-2 receptor antagonist and methods of making
HK40104628A (en) Crystalline forms of gnrh receptor antagonist and preparation method therefor
GB202506745D0 (en) SRSF1 antagonist
GB202413855D0 (en) Srsf1 antagonist
AU2021407138A9 (en) Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist